Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations

N. Matsubara, Y. Loriot, E. F. Burgess, S. H. Park, R. A. Huddart,J. H. Ku, B. Tran, S. Triantos, K. Deprince, S. Mukhopadhyay, R. Hemaya, J. Zhuo, A. O. Siefker-Radtke

ANNALS OF ONCOLOGY（2023）

引用 0|浏览0